APA (7th ed.) Citation

Flan, L., Audousset, C., Perez, T., Prévotat, A., Duthoit, L., Boldron, A., . . . Tetart, M. (2024). WS16.05 Changes in Aspergillus parameters and antifungal prescriptions in adults with cystic fibrosis treated by elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis, 23, S31. https://doi.org/10.1016/S1569-1993(24)00203-0

Chicago Style (17th ed.) Citation

Flan, L., C. Audousset, T. Perez, A. Prévotat, L. Duthoit, A. Boldron, N. Paris, O. Le Rouzic, and M. Tetart. "WS16.05 Changes in Aspergillus Parameters and Antifungal Prescriptions in Adults with Cystic Fibrosis Treated by Elexacaftor/tezacaftor/ivacaftor." Journal of Cystic Fibrosis 23 (2024): S31. https://doi.org/10.1016/S1569-1993(24)00203-0.

MLA (9th ed.) Citation

Flan, L., et al. "WS16.05 Changes in Aspergillus Parameters and Antifungal Prescriptions in Adults with Cystic Fibrosis Treated by Elexacaftor/tezacaftor/ivacaftor." Journal of Cystic Fibrosis, vol. 23, 2024, p. S31, https://doi.org/10.1016/S1569-1993(24)00203-0.